scholarly journals Cognitive symptoms after COVID-19

2021 ◽  
Vol 1 ◽  
pp. S16-S24
Author(s):  
M. Altuna ◽  
Mª.B. Sánchez-Saudinós ◽  
A. Lleó
Keyword(s):  
Cognitive Symptoms

Difficulties in functional recovery in schizophrenia: negative and cognitive symptoms

Psihiatru ro ◽  
2018 ◽  
Vol 3 (54) ◽  
pp. 30
Author(s):  
Marco Muntean ◽  
Ileana Marinescu ◽  
Dragoș Marinescu ◽  
Lavinia Hogea ◽  
Claudia Suru ◽  
...  
Keyword(s):  
Functional Recovery ◽  
Cognitive Symptoms

Cinnarizine - Potential Trigger of the Dopamine Supersensitivity Psychosis in Patients with Paranoid Schizophrenia Particular neurobiochemical model

2019 ◽  
Vol 70 (8) ◽  
pp. 3003-3007
Author(s):  
Ileana Marinescu ◽  
Puiu Olivian Stovicek ◽  
Dragos Marinescu ◽  
Marius Toma Papacocea ◽  
Mihnea Costin Manea ◽  
...  
Keyword(s):  
Sensory Integration ◽  
Paranoid Schizophrenia ◽  
D2 Receptor ◽  
Point Of View ◽  
Cognitive Symptoms ◽  
Receptor Blocking ◽  
Clinical Reality ◽  
Potential Trigger ◽  
Dopamine Supersensitivity ◽  
Blocking Capacity

Supersensitivity psychosis is a subdiagnosed clinical reality. This entity, however, is insufficiently elucidated from the point of view of the neurobiochemical mechanisms involved in the pathogenesis. The combination of an antipsychotic with a high D2 receptor blocking capacity and a neuroleptic-like substance such as cinnarizine trigger the dopaminergic hypersensitivity mechanisms. This stimulates the sensitivity for dopamine in the prefrontal cortex, ameliorating the negative and cognitive symptoms at the thalamic level, remodeling sensory integration and decreasing tinnitus, as well as in the cerebral tonsil, consequently decreasing the risk of antisocial behavior.

Vitamin D Levels, APOE Allele, and MRI Volumetry Assessed by NeuroQuant in Norwegian Adults with Cognitive Symptoms

2021 ◽  
Vol 79 (1) ◽  
pp. 311-321
Author(s):  
Jelena Zugic Soares ◽  
Renate Pettersen ◽  
Jūratė Šaltytė Benth ◽  
Karin Persson ◽  
Carsten Strobel ◽  
...  
Keyword(s):  
Vitamin D ◽  
Late Onset ◽  
Apoe Genotype ◽  
Serum Levels ◽  
Grey Matter Volume ◽  
Cognitive Symptoms ◽  
Cross Sectional ◽  
Brain Volumes ◽  
Vitamin D Levels ◽  
Mri Volumetry

Background: Allele ɛ4 of the apolipoprotein (APOE ∈4) gene is the strongest known genetic risk factor for late-onset sporadic Alzheimer’s disease. A possible relationship between vitamin D and APOE is not yet clear. Objective: In this exploratory, cross-sectional study, we examined the association between serum levels of 25-hydroxyvitamin D [25(OH)D] and brain volumes and the associations of both serum levels of 25(OH)D and APOE polymorphism to brain volumes in 127 persons (mean age 66 years) with cognitive symptoms. Methods: All subjects were examined with fully automated software for MRI volumetry, NeuroQuant. Results: After adjustment for relevant covariates, higher serum 25(OH)D levels were associated with greater volumes of cortical gray matter on both left (p = 0.02) and right (p = 0.04) sides. When both 25(OH)D levels and APOE genotype were used as the main covariates, no significant associations were found between vitamin D level and brain volume in any of the 11 brain regions. In adjusted models, only homozygous but not heterozygous APOE ∈4 allele carriers had significantly larger inferior lateral ventricles (p = 0.003) and smaller hippocampal volume (p = 0.035) than those without ɛ4. Homozygous APOE ∈4 carriers also had significantly higher vitamin D levels (p = 0.009) compared to persons without the APOE ∈4 allele. Conclusion: Higher vitamin D levels might have a preserving effect on cortical grey matter volume.

scholarly journals Impact of APOE ε4 genotype on initial cognitive symptoms differs for Alzheimer’s and Lewy body neuropathology

2021 ◽  
Vol 13 (1) ◽  
Author(s):  
Jagan A. Pillai ◽  
James Bena ◽  
Aaron Bonner-Jackson ◽  
James B. Leverenz
Keyword(s):  
Lewy Body ◽  
Statistical Significance ◽  
Carrier Status ◽  
Initial Symptom ◽  
Cognitive Symptoms ◽  
Clinical Dementia Rating ◽  
Apoe Ε4 ◽  
Initial Symptoms ◽  
Adjusted Model ◽  
The Impact

Abstract Background APOE ε4 carrier status is known to increase odds of amnestic presentations with Alzheimer’s pathology. It is unknown how APOE ε4 carrier status impacts odds of specific initial cognitive symptoms in the presence of Lewy body pathology. Here we evaluate the impact of APOE ε4 genotype on initial cognitive symptoms among those with Alzheimer’s disease pathology (ADP) and Lewy-related pathology (LRP). Methods A retrospective cohort study of 2288 participants with neuropathology confirmed ADP or LRP in the National Alzheimer’s Coordinating Center database, who had initial cognitive symptoms documented and had a Clinical Dementia Rating-Global (CDR-G) score ≤ 1 (cognitively normal, MCI, or early dementia). Unadjusted and adjusted logistic regression models taking into account age at evaluation, sex, and education examined the relationship between APOE ε4 genotype and initial symptoms (memory, executive, language visuospatial) among ADP with LRP and ADP-LRP groups. Results One thousand three hundred three participants met criteria for ADP alone, 90 for LRP alone, and 895 for co-existing ADP and LRP (ADP-LRP). Younger age increased odds of non-amnestic symptoms across all three groups. In the adjusted model among ADP, APOE ε4 carriers had higher odds of amnestic initial symptoms 1.5 [95% CI, 1.7–2.14, p = 0.003] and lower odds of initial language symptoms 0.67 [95% CI, 0.47–0.96, p = 0.03] than non-carriers. The odds for these two symptoms were not different between ADP and mixed ADP-LRP groups. Female sex and higher education increased odds of initial language symptoms in the ADP group in the adjusted model. In the unadjusted model, APOE ε4 carriers with LRP had a higher odds of visuospatial initial symptoms 21.96 [95% CI, 4.02–110.62, p < 0.0001], while no difference was noted for initial executive/attention symptoms. Among LRP, the odds of APOE ε4 on amnestic symptom was not significant; however, the interaction effect evaluating the difference in odds ratios of amnestic symptom between ADP and LRP groups also did not reach statistical significance. Conclusions The odds of specific initial cognitive symptoms differed between ADP and LRP among APOE ε4 carriers compared to non-carriers. The odds of initial amnestic symptom was higher among ADP APOE ε4 carriers and the odds of visuospatial initial symptom was higher with LRP APOE ε4 carriers. This supports the hypothesis that APOE ε4 differentially impacts initial cognitive symptoms together with underlying neuropathology.

Sign in / Sign up

Export Citation Format

Share Document